Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Jun 2025 value amounting to $748,000.

  • Day One Biopharmaceuticals' Cash from Financing Activities fell 42.33% to $748,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $204.0 million, marking a year-over-year increase of 9816.92%. This contributed to the annual value of $203.3 million for FY2024, which is 23.96% up from last year.
  • As of Q2 2025, Day One Biopharmaceuticals' Cash from Financing Activities stood at $748,000, which was down 59.59% from $1.9 million recorded in Q4 2024.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash from Financing Activities peaked at $200.1 million during Q3 2024, and registered a low of $48,000 during Q1 2024.
  • In the last 3 years, Day One Biopharmaceuticals' Cash from Financing Activities had a median value of $1.2 million in 2023 and averaged $40.9 million.
  • Within the past 5 years, the most significant YoY rise in Day One Biopharmaceuticals' Cash from Financing Activities was 173,895.65% (2024), while the steepest drop was 99.20% (2024).
  • Day One Biopharmaceuticals' Cash from Financing Activities (Quarterly) stood at $1.9 million in 2022, then plummeted by 68.87% to $597,000 in 2023, then surged by 210.05% to $1.9 million in 2024, then crashed by 42.33% to $748,000 in 2025.
  • Its Cash from Financing Activities was $748,000 in Q2 2025, compared to $1.9 million in Q4 2024 and $200.1 million in Q3 2024.